LY96 and thyroid cancer: The cBioportal database was used to reveal the mutation of LY96 in cancers, and results indicated that the highest alteration frequency occurred in prostate adenocarcinoma, hepatocellular carcinoma, and invasive breast carcinoma, whereas LY96 showed the lowest alteration frequency in well-differentiated thyroid cancer, thymic epithelial tumor, and non-seminomatous germ cell tumor (Figure 5A).